Farmington, CT – According to filings with the U.S. Securities and Exchange Commission, Torigen is raising $13,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ashley Kalinauskas played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Torigen
Torigen Pharmaceuticals is focused on veterinary cancer care. Our product, VetiVax, is a revolutionary cancer immunotherapy that uses the patients own tumor cells to create a personalized treatment which educates the immune system to recognize the tumor as foreign. With over 12 years of supporting research, VetiVax allows for a variety of tumor antigens to be presented to the immune system. This abundant choice increases the likelihood of a successful response.

To learn more about Torigen, visit http://www.torigen.com/

Contact:
Ashley Kalinauskas, Chief Executive Officer
860-519-9956

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved